Danish Chemometec raises its outlook for fiscal year 2026/27 following higher-than-expected demand for the company’s instruments, with NC-203 having been an important growth driver, as well as lower-than-expected costs.
Revenue is now expected to amount to DKK 570–605 million, compared with the previous forecast of DKK 560–590 million. The forecast for EBITDA is raised to DKK 335–360 million from DKK 330–345 million.
The company also reports that revenue in the first quarter increased 28 percent to DKK 160.0 million. EBITDA rose to DKK 100.3 million, corresponding to a margin of 63 percent, compared with 55 percent a year earlier.
The interim report will be published on 5 November.
